Literature DB >> 24332164

MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis.

Jing Zhang1, Ye Cheng1, Wei Cui1, Meixi Li1, Bin Li1, Li Guo2.   

Abstract

Mammalian noncoding microRNAs (miRNAs) are suggested to be involved in immune system function. We found that miR-155 expression was highly correlated with disease severity in patients with multiple sclerosis and mice with experimental autoimmune encephalomyelitis (EAE). Knockdown of miR-155 resulted in low Th1 and Th17 cells and mild EAE, and its overexpression led to more Th1 and Th17 cells and severe EAE. MiR-155 promoted the development of inflammatory Th17/Th1 cell subsets. These findings demonstrate that miR-155 confers susceptibility to EAE by affecting inflammatory T cell responses and can be a new target for therapy of multiple sclerosis.
© 2013.

Entities:  

Keywords:  Experimental autoimmune encephalomyelitis; MicroRNAs; Multiple sclerosis; Th1 cells; Th17 cells

Mesh:

Substances:

Year:  2013        PMID: 24332164     DOI: 10.1016/j.jneuroim.2013.09.019

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  62 in total

1.  MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis.

Authors:  Ankita Singh; Pradeepta Sekhar Patro; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2018-12-03       Impact factor: 2.980

2.  MicroRNA-155 is required for clearance of Streptococcus pneumoniae from the nasopharynx.

Authors:  Chris P Verschoor; Michael G Dorrington; Kyle E Novakowski; Julie Kaiser; Katherine Radford; Parameswaran Nair; Varun Anipindi; Charu Kaushic; Michael G Surette; Dawn M E Bowdish
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

Review 3.  MicroRNA control of B cell tolerance, autoimmunity and cancer.

Authors:  Changchun Xiao; David Nemazee; Alicia Gonzalez-Martin
Journal:  Semin Cancer Biol       Date:  2020-08       Impact factor: 15.707

4.  Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.

Authors:  Jaspreet Singh; Mandar Deshpande; Hamid Suhail; Ramandeep Rattan; Shailendra Giri
Journal:  J Neuroimmune Pharmacol       Date:  2015-08-16       Impact factor: 4.147

5.  microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease.

Authors:  Aaron D Thome; Ashley S Harms; Laura A Volpicelli-Daley; David G Standaert
Journal:  J Neurosci       Date:  2016-02-24       Impact factor: 6.167

6.  Glucocorticoids regulate the proliferation of T cells via miRNA-155 in septic shock.

Authors:  Ying Chen; Guang Wang; Zhongmin Liu; Shiji Wang; Yushan Wang
Journal:  Exp Ther Med       Date:  2016-10-20       Impact factor: 2.447

Review 7.  MicroRNA regulation of lymphocyte tolerance and autoimmunity.

Authors:  Laura J Simpson; K Mark Ansel
Journal:  J Clin Invest       Date:  2015-06-01       Impact factor: 14.808

Review 8.  MicroRNA-mediated regulation of T helper type 17/regulatory T-cell balance in autoimmune disease.

Authors:  Cuilian Liu; Haoran Yang; Weiyun Shi; Ting Wang; Qingguo Ruan
Journal:  Immunology       Date:  2018-09-10       Impact factor: 7.397

9.  Expression of microRNA-155 in inflammatory cells modulates liver injury.

Authors:  Delia Blaya; Beatriz Aguilar-Bravo; Fengjie Hao; Silvia Casacuberta-Serra; Mar Coll; Luis Perea; Júlia Vallverdú; Isabel Graupera; Elisa Pose; Laura Llovet; Jordi Barquinero; Francisco Javier Cubero; Juan Caballería; Pere Ginès; Pau Sancho-Bru
Journal:  Hepatology       Date:  2018-05-02       Impact factor: 17.425

10.  MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function.

Authors:  Nina C Zitzer; Katiri Snyder; Xiamoei Meng; Patricia A Taylor; Yvonne A Efebera; Steven M Devine; Bruce R Blazar; Ramiro Garzon; Parvathi Ranganathan
Journal:  J Immunol       Date:  2018-05-02       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.